SLC5A2 and type 2 diabetes mellitus: Specifically, a population-based cohort study comparing patients with T2DM who are new users of SGLT-2 inhibitors with those receiving DPP-4is showed a Hazard Ratio of 2.85 (95%CI 1.99–4.08) [19].